Immunocore Holdings PLC
IMCR31.980USD
+1.060+3.43%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.59BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immunocore Holdings PLC Unternehmen
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Immunocore Holdings PLC Informationen
BörsenkürzelIMCR
Name des UnternehmensImmunocore Holdings PLC
IPO-datumFeb 05, 2021
CEOJallal (Bahija)
Anzahl der mitarbeiter493
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 05
Addresse92 Park Drive Milton Park
StadtABINGDON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlOX14 4RY
Telefon441235438600
Websitehttps://www.immunocore.com/
BörsenkürzelIMCR
IPO-datumFeb 05, 2021
CEOJallal (Bahija)
Führungskräfte von Immunocore Holdings PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 24
Aktualisiert: Sat, Jan 24
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
14.19%
RTW Investments L.P.
9.78%
Wellington Management Company, LLP
9.60%
Fidelity Management & Research Company LLC
8.81%
PRIMECAP Management Company
7.54%
Andere
50.08%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
14.19%
RTW Investments L.P.
9.78%
Wellington Management Company, LLP
9.60%
Fidelity Management & Research Company LLC
8.81%
PRIMECAP Management Company
7.54%
Andere
50.08%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
43.78%
Hedge Fund
28.59%
Investment Advisor/Hedge Fund
24.70%
Venture Capital
1.71%
Research Firm
1.62%
Private Equity
0.77%
Pension Fund
0.57%
Family Office
0.05%
Individual Investor
0.03%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
302
50.63M
101.68%
-9.63M
2025Q3
300
49.40M
99.22%
-6.80M
2025Q2
293
49.19M
99.31%
-10.02M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
7.06M
14.19%
-3.76K
-0.05%
Sep 30, 2025
RTW Investments L.P.
4.87M
9.78%
--
--
Sep 30, 2025
Wellington Management Company, LLP
4.78M
9.6%
-352.01K
-6.86%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.39M
8.81%
-432.38K
-8.97%
Sep 30, 2025
PRIMECAP Management Company
3.75M
7.54%
-16.91K
-0.45%
Sep 30, 2025
Bellevue Asset Management AG
2.80M
5.62%
--
--
Sep 30, 2025
Tang Capital Management, LLC
2.61M
5.23%
+300.00K
+13.01%
Oct 17, 2025
Baker Bros. Advisors LP
2.32M
4.66%
--
--
Sep 30, 2025
Deep Track Capital LP
1.80M
3.61%
--
--
Sep 30, 2025
BVF Partners L.P.
1.57M
3.16%
+550.00K
+53.70%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Virtus LifeSci Biotech Products ETF
1.49%
Tema Oncology ETF
1.11%
ALPS Medical Breakthroughs ETF
0.7%
ProShares Ultra Nasdaq Biotechnology
0.19%
SPDR S&P International Small Cap ETF
0.17%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Intl Small Cap Equity Factor ETF
0.12%
iShares Biotechnology ETF
0.1%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Mehr Anzeigen
Virtus LifeSci Biotech Products ETF
Anteil1.49%
Tema Oncology ETF
Anteil1.11%
ALPS Medical Breakthroughs ETF
Anteil0.7%
ProShares Ultra Nasdaq Biotechnology
Anteil0.19%
SPDR S&P International Small Cap ETF
Anteil0.17%
Invesco Nasdaq Biotechnology ETF
Anteil0.13%
iShares Intl Small Cap Equity Factor ETF
Anteil0.12%
iShares Biotechnology ETF
Anteil0.1%
SPDR Portfolio Developed World ex-US ETF
Anteil0.01%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
